



GLP-1 Cost Savings Opportunity: Trulicity to Ozempic

Drug Profile

	Ozempic (semaglutide)	Trulicity (dulaglutide)
Mechanism of Action	GLP-1 Agonist	GLP-1 Agonist
Indications	Type-2 Diabetes	Type-2 Diabetes
Pearls/Clinical Efficacy	<ul style="list-style-type: none"> • Delays progression of CKD [1] • Reduces the risk of diabetic nephropathy [1] • Mean weight loss of 4.6kg [2] • Reduces A1C by 1.5%-1.8% [2] 	<ul style="list-style-type: none"> • Same MACE reduction as Ozempic • Mean weight loss of 3.0 kg [2] • Reduces A1C by 1.1%-1.4% [2]

1. American Diabetes Association. (2024). 10. Cardiovascular disease and risk management: Standards of care in diabetes—2024. *Diabetes Care*, 47(Supplement 1), S165–S190. <https://doi.org/10.2337/dc24-S010>
2. Pratley, R. E., Aroda, V. R., Lingvay, I., Lüdemann, J., Andreassen, C., Navarria, A., Viljoen, A., & SUSTAIN 7 investigators (2018). Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. *The lancet. Diabetes & endocrinology*, 6(4), 275–286. [https://doi.org/10.1016/S2213-8587\(18\)30024-X](https://doi.org/10.1016/S2213-8587(18)30024-X)

Optimizing Cost-Savings: Trulicity to Ozempic

Prices were obtained using quantities of **2mL** (28-day supply) and **6mL** (90-day supply) for Trulicity. Quantities of **3mL** (28-day supply) and **9mL** (90-day supply) for Ozempic due to variable day supplies listed for once-weekly injections.

Aetna

Supply (days)	Ozempic (semaglutide)	Trulicity (dulaglutide)	Cost savings/script
28	\$748.29	\$796.96	\$48.67
84	\$2,492.17	\$2,534.69	\$42.52

Data obtained from Aetna claims

Humana

Supply (days)	Ozempic (semaglutide)	Trulicity (dulaglutide)	Cost savings/script
28	681.19	\$809.16	\$127.97
84	1,946.23	\$2,666.73	\$720.50

Data obtained from Humana Claims



Mercy Care

Supply (days)	Ozempic (semaglutide)	Trulicity (dulaglutide)	Cost savings/script
28	\$879.72	\$906.89	\$27.17
84	\$2,586.89	\$2,619.86	\$32.97

Data obtained from Mercy Care claims

The following payers **DO NOT** demonstrate a cost-savings opportunity.

However, a transition to Ozempic could be recommended from an efficacy approach if an increase in any or all of the following is desired: renal protection, weight loss, A1C reduction.

Medicare

Supply (days)	Ozempic (semaglutide)	Trulicity (dulaglutide)	Cost savings/script
28	\$146.70	\$103.65	No savings (+\$43.05)
84	\$293.72	\$278.25	No savings (+\$15.47)

Data obtained from Medicare claims

UnitedHealthcare

Supply (days)	Ozempic (semaglutide)	Trulicity (dulaglutide)	Cost savings/script
28	\$837.69	\$748.06	No savings (+\$89.63)
84	\$2,154.16	\$1,889.22	No savings (+\$264.94)

Data obtained from UnitedHealthcare claims

Intel Connected Care

Supply (days)	Ozempic (semaglutide)	Trulicity (dulaglutide)	Cost savings/script
28	\$92.07	\$92.29	\$0.22
84	\$268.43	\$269.08	\$0.65

Data obtained from Intel Connected Care claims